187 related articles for article (PubMed ID: 19442208)
1. Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke.
Yamamoto T; Takahara A
Curr Top Med Chem; 2009; 9(4):377-95. PubMed ID: 19442208
[TBL] [Abstract][Full Text] [Related]
2. N-type calcium channel blockers: novel therapeutics for the treatment of pain.
Schroeder CI; Doering CJ; Zamponi GW; Lewis RJ
Med Chem; 2006 Sep; 2(5):535-43. PubMed ID: 17017994
[TBL] [Abstract][Full Text] [Related]
3. An orally available Ca
Kutzsche J; Guzman GA; Willuweit A; Kletke O; Wollert E; Gering I; Jürgens D; Breitkreutz J; Stark H; Beck-Sickinger AG; Klöcker N; Hidalgo P; Willbold D
Br J Pharmacol; 2024 Jun; 181(12):1734-1756. PubMed ID: 38157867
[TBL] [Abstract][Full Text] [Related]
4. Challenging the catechism of therapeutics for chronic neuropathic pain: Targeting CaV2.2 interactions with CRMP2 peptides.
Feldman P; Khanna R
Neurosci Lett; 2013 Dec; 557 Pt A(0 0):27-36. PubMed ID: 23831344
[TBL] [Abstract][Full Text] [Related]
5. A novel series of pyrazolylpiperidine N-type calcium channel blockers.
Subasinghe NL; Wall MJ; Winters MP; Qin N; Lubin ML; Finley MF; Brandt MR; Neeper MP; Schneider CR; Colburn RW; Flores CM; Sui Z
Bioorg Med Chem Lett; 2012 Jun; 22(12):4080-3. PubMed ID: 22608964
[TBL] [Abstract][Full Text] [Related]
6. Ziconotide: can we use it in palliative care?
Prommer EE
Am J Hosp Palliat Care; 2005; 22(5):369-74. PubMed ID: 16225359
[TBL] [Abstract][Full Text] [Related]
7. Targeting chronic and neuropathic pain: the N-type calcium channel comes of age.
Snutch TP
NeuroRx; 2005 Oct; 2(4):662-70. PubMed ID: 16489373
[TBL] [Abstract][Full Text] [Related]
8. Analgesic effect of highly reversible ω-conotoxin FVIA on N type Ca2+ channels.
Lee S; Kim Y; Back SK; Choi HW; Lee JY; Jung HH; Ryu JH; Suh HW; Na HS; Kim HJ; Rhim H; Kim JI
Mol Pain; 2010 Dec; 6():97. PubMed ID: 21172037
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel tetrahydroisoquinoline derivatives as orally active N-type calcium channel blockers with high selectivity for hERG potassium channels.
Ogiyama T; Inoue M; Honda S; Yamada H; Watanabe T; Gotoh T; Kiso T; Koakutsu A; Kakimoto S; Shishikura J
Bioorg Med Chem; 2014 Dec; 22(24):6899-907. PubMed ID: 25456079
[TBL] [Abstract][Full Text] [Related]
10. 3-Benzamides and 3,4,5-trimethoxyphenyl amines as calcium channel blockers.
Kang B; Oh JA; Lee JY; Rhim H; Yune TY; Park Choo HY
Bioorg Med Chem; 2015 Sep; 23(18):6166-72. PubMed ID: 26296911
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and SAR of 4-aminocyclopentapyrrolidines as orally active N-type calcium channel inhibitors for inflammatory and neuropathic pain.
Beebe X; Yeung CM; Darczak D; Shekhar S; Vortherms TA; Miller L; Milicic I; Swensen AM; Zhu CZ; Banfor P; Wetter JM; Marsh KC; Jarvis MF; Scott VE; Schrimpf MR; Lee CH
Bioorg Med Chem Lett; 2013 Sep; 23(17):4857-61. PubMed ID: 23876987
[TBL] [Abstract][Full Text] [Related]
12. Ziconotide--a novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain--a short review.
Klotz U
Int J Clin Pharmacol Ther; 2006 Oct; 44(10):478-83. PubMed ID: 17063978
[TBL] [Abstract][Full Text] [Related]
13. Autoradiographic localization of N-type VGCCs in gerbil hippocampus and failure of omega-conotoxin MVIIA to attenuate neuronal injury after transient cerebral ischemia.
Azimi-Zonooz A; Kawa CB; Dowell CD; Olivera BM
Brain Res; 2001 Jul; 907(1-2):61-70. PubMed ID: 11430886
[TBL] [Abstract][Full Text] [Related]
14. A nonadherent cell-based HTS assay for N-type calcium channel using calcium 3 dye.
Lubin ML; Reitz TL; Todd MJ; Flores CM; Qin N; Xin H
Assay Drug Dev Technol; 2006 Dec; 4(6):689-94. PubMed ID: 17199507
[TBL] [Abstract][Full Text] [Related]
15. N- and L-type calcium channels blocker cilnidipine ameliorates neuropathic pain.
Yamamoto S; Suzuki Y; Ono H; Kume K; Ohsawa M
Eur J Pharmacol; 2016 Dec; 793():66-75. PubMed ID: 27823932
[TBL] [Abstract][Full Text] [Related]
16. Discovery and optimization of a novel series of pyrazolyltetrahydropyran N-type calcium channel (Ca
Wall MJ; Subasinghe NL; Winters MP; Lubin ML; Finley MFA; Qin N; Brandt MR; Neeper MP; Schneider CR; Colburn RW; Flores CM; Sui Z
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3780-3783. PubMed ID: 30337231
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the inhibitory effect of dihydropyridines on N-type calcium channel by virtual three-dimensional pharmacophore modeling.
Ogihara T; Kano T; Kakinuma C
Arzneimittelforschung; 2009; 59(6):283-8. PubMed ID: 19634509
[TBL] [Abstract][Full Text] [Related]
18. Analgesic (omega)-conotoxins CVIE and CVIF selectively and voltage-dependently block recombinant and native N-type calcium channels.
Berecki G; Motin L; Haythornthwaite A; Vink S; Bansal P; Drinkwater R; Wang CI; Moretta M; Lewis RJ; Alewood PF; Christie MJ; Adams DJ
Mol Pharmacol; 2010 Feb; 77(2):139-48. PubMed ID: 19892914
[TBL] [Abstract][Full Text] [Related]
19. Analgesic effects of a substituted N-triazole oxindole (TROX-1), a state-dependent, voltage-gated calcium channel 2 blocker.
Abbadie C; McManus OB; Sun SY; Bugianesi RM; Dai G; Haedo RJ; Herrington JB; Kaczorowski GJ; Smith MM; Swensen AM; Warren VA; Williams B; Arneric SP; Eduljee C; Snutch TP; Tringham EW; Jochnowitz N; Liang A; Euan MacIntyre D; McGowan E; Mistry S; White VV; Hoyt SB; London C; Lyons KA; Bunting PB; Volksdorf S; Duffy JL
J Pharmacol Exp Ther; 2010 Aug; 334(2):545-55. PubMed ID: 20439438
[TBL] [Abstract][Full Text] [Related]
20. A peripherally acting, selective T-type calcium channel blocker, ABT-639, effectively reduces nociceptive and neuropathic pain in rats.
Jarvis MF; Scott VE; McGaraughty S; Chu KL; Xu J; Niforatos W; Milicic I; Joshi S; Zhang Q; Xia Z
Biochem Pharmacol; 2014 Jun; 89(4):536-44. PubMed ID: 24726441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
